[{"id":"888b5254-e6dd-48b6-9b64-58ed9e870a5a","acronym":"KEYNOTE-B77","url":"https://clinicaltrials.gov/study/NCT04570332","created_at":"2021-01-18T21:49:33.587Z","updated_at":"2025-02-25T16:10:40.165Z","phase":"Phase 2","brief_title":"BO-112 With Pembrolizumab in Unresectable Malignant Melanoma","source_id_and_acronym":"NCT04570332 - KEYNOTE-B77","lead_sponsor":"Highlight Therapeutics","biomarkers":" BRAF • CD4","pipe":"","alterations":" ","tags":["BRAF • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • polyinosinic:polycytidylic acid (BO-112)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/30/2020","start_date":" 12/30/2020","primary_txt":" Primary completion: 10/03/2023","primary_completion_date":" 10/03/2023","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-01-29"},{"id":"a6ab7702-d3f8-4abb-8ca2-2914ef3e190d","acronym":"Noelia","url":"https://clinicaltrials.gov/study/NCT05265650","created_at":"2022-03-03T13:28:18.563Z","updated_at":"2024-07-02T16:36:07.185Z","phase":"Phase 1/2","brief_title":"Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC","source_id_and_acronym":"NCT05265650 - Noelia","lead_sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","biomarkers":" EGFR • ALK • CD4","pipe":"","alterations":" ","tags":["EGFR • ALK • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • polyinosinic:polycytidylic acid (BO-112)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/13/2022","start_date":" 06/13/2022","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2022-07-19"}]